| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.6 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |